Obesity landscape set for transformation by highly innovate drug entrants; Report

While the current obesity treatment market has a high level of unmet need, the therapeutic landscape could be transformed by a highly innovative and diverse pipeline that includes 248 products in active development.

According to business intelligence provider GBI Research’s latest report, despite the current market’s clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, with 39% of the pipeline products with disclosed molecular targets classified as first-in-class.

Angel Wong, senior analyst for GBI Research, says that while most pipeline products target gut hormone receptors, the remainder target a wide range of processes thought to be dysregulated in obesity, such as angiogenesis, insulin signaling, inflammation, fat absorption, lipid synthesis, and metabolism.